NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

September 05, 2023

In this second episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss the techniques used such as endoscopic ultrasound–guided biopsies to collect adequate tissue to perform genomic analyses in pancreatic cancer, and the likelihood for finding actionable mutations in this population.

September 05, 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

September 05, 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

September 04, 2023

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

September 04, 2023

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

August 29, 2023

In this first episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss how endoscopic ultrasound has changed the diagnosis of pancreatic cancer and how it may also be utilized to guide personalized treatment in nonmetastatic adenocarcinomas.

August 29, 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

August 29, 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

August 25, 2023

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

August 22, 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

August 22, 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

August 21, 2023

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

August 21, 2023

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

August 15, 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

August 15, 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

August 10, 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

August 10, 2023

An overview of ongoing research in the endometrial cancer treatment space.

August 03, 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

August 03, 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

July 31, 2023

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer